Subsequent Events	6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events IBSA License Agreement - Profhilo® On July 7, 2026, the Company entered into a License, Supply and Distribution Agreement (the “IBSA Agreement”) with IBSA Institut Biochimique SA (“IBSA”). Under the IBSA Agreement, IBSA granted to the Company an exclusive right and license to develop, commercialize and distribute Profhilo®, an injectable hyaluronic acid product for skin-quality applications, in the United States for use in the aesthetics and dermatological fields (the “Field”). The IBSA Agreement also provides the Company with the right to negotiate for certain additional products in the Profhilo® brand family and related line extensions in the Field within the United States. Under the terms of the IBSA Agreement, the Company will be responsible for development activities required to obtain U.S. regulatory approval for Profhilo®, as well as commercialization activities following approval. The IBSA Agreement does not require the Company to make any upfront payment or milestone payments to IBSA. Beginning in the fourth year following the commercial launch of Profhilo® in the United States, the Company will be subject to certain minimum purchase requirements. Failure to satisfy such requirements may result in the conversion of the Company’s exclusive rights to non-exclusive rights or termination of the IBSA Agreement, subject to certain exceptions. Because the timing of regulatory approval and commercial launch is uncertain, the Company cannot reasonably estimate the future financial impact of its development and commercialization activities related to Profhilo®, including any potential obligations under the minimum purchase requirements. The initial term of the IBSA Agreement is fifteen (15) years from the date of the first U.S. Food and Drug Administration approval of Profhilo®. The IBSA Agreement may be renewed for successive five (5)-year terms, subject to the terms set forth in the IBSA Agreement. Symatese EU Amendments On August 3, 2026, the Company and Symatese entered into a series of agreements (collectively, the “Symatese EU Amendments”) that amended and expanded the Company’s commercialization rights under the Symatese Europe Agreement. As a result of the Symatese EU Amendments, the Company has exclusive rights to commercialize and distribute the full line of Evolysse® injectable HA gel products in each of (i) Europe, (ii) Canada and (iii) Australia and New Zealand (each, a “Sub-Territory” and collectively, the “Sub-Territories”) for use in the aesthetics and dermatological fields. Symatese is responsible, at its sole expense, for obtaining and maintaining regulatory approvals for the products in the Sub-Territories. Under the Symatese EU Amendments, the Company is required to make aggregate upfront payments of €1,420 and may be required to make additional payments of up to €2,880 upon receipt of certain regulatory approvals and completion of certain registration processes. The Company is subject to minimum purchase requirements under the Symatese Europe Agreement, as amended. Failure to satisfy the purchase requirements may result in a reduction or termination of the Company’s exclusive rights in the applicable Sub-Territory, subject to certain exceptions. The initial term for each Sub-Territory is 15 years from the first applicable regulatory approval in such Sub-Territory and will automatically renew for successive five-year terms, subject to the terms of the Symatese Europe Agreement.

On July 7, 2026, the Company entered into a License, Supply and Distribution Agreement (the “IBSA Agreement”) with IBSA Institut Biochimique SA (“IBSA”). Under the IBSA Agreement, IBSA granted to the Company an exclusive right and license to develop, commercialize and distribute Profhilo®, an injectable hyaluronic acid product for skin-quality applications, in the United States for use in the aesthetics and dermatological fields (the “Field”). The IBSA Agreement also provides the Company with the right to negotiate for certain additional products in the Profhilo® brand family and related line extensions in the Field within the United States.

Under the terms of the IBSA Agreement, the Company will be responsible for development activities required to obtain U.S. regulatory approval for Profhilo®, as well as commercialization activities following approval. The IBSA Agreement does not require the Company to make any upfront payment or milestone payments to IBSA. Beginning in the fourth year following the commercial launch of Profhilo® in the United States, the Company will be subject to certain minimum purchase requirements. Failure to satisfy such requirements may result in the conversion of the Company’s exclusive rights to non-exclusive rights or termination of the IBSA Agreement, subject to certain exceptions. Because the timing of regulatory

approval and commercial launch is uncertain, the Company cannot reasonably estimate the future financial impact of its development and commercialization activities related to Profhilo®, including any potential obligations under the minimum purchase requirements.

The initial term of the IBSA Agreement is fifteen (15) years from the date of the first U.S. Food and Drug Administration approval of Profhilo®. The IBSA Agreement may be renewed for successive five (5)-year terms, subject to the terms set forth in the IBSA Agreement.

On August 3, 2026, the Company and Symatese entered into a series of agreements (collectively, the “Symatese EU Amendments”) that amended and expanded the Company’s commercialization rights under the Symatese Europe Agreement. As a result of the Symatese EU Amendments, the Company has exclusive rights to commercialize and distribute the full line of Evolysse® injectable HA gel products in each of (i) Europe, (ii) Canada and (iii) Australia and New Zealand (each, a “Sub-Territory” and collectively, the “Sub-Territories”) for use in the aesthetics and dermatological fields. Symatese is responsible, at its sole expense, for obtaining and maintaining regulatory approvals for the products in the Sub-Territories.

Under the Symatese EU Amendments, the Company is required to make aggregate upfront payments of €1,420 and may be required to make additional payments of up to €2,880 upon receipt of certain regulatory approvals and completion of certain registration processes.

The Company is subject to minimum purchase requirements under the Symatese Europe Agreement, as amended. Failure to satisfy the purchase requirements may result in a reduction or termination of the Company’s exclusive rights in the applicable Sub-Territory, subject to certain exceptions. The initial term for each Sub-Territory is 15 years from the first applicable regulatory approval in such Sub-Territory and will automatically renew for successive five-year terms, subject to the terms of the Symatese Europe Agreement.